Disoxaril
Based on 1 Customer Validation
Disoxaril (WIN-51711) is an antivirus agent with activity against poliovirus types 1 and 2. Disoxaril inserts into the hydrophobic interior of virus capsid protein VP1 to stabilize virion conformation, inhibits poliovirus uncoating, and prevents viral RNA release and synthesis. Disoxaril can be used for the research of poliovirus infection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 96.50%
- CAS No.: 87495-31-6
- Formule: C20H26N2O3
- Masse moléculaire:342.43
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Antiviral Compound Library
HY-L027
-
Human Metabolite Library
HY-L123
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | CC50 |
21 μM
Compound: Disoxaril
|
Antiviral activity against Human rhinovirus type 14 in human HeLa Ohio-1 cells
Antiviral activity against Human rhinovirus type 14 in human HeLa Ohio-1 cells
|
[PMID: 18590964] |
| HeLa | CC50 |
37 μM
Compound: WIN-51711
|
Compound concentration required to reduce the viability of mock-infected HeLa cells by 50%, was reported.
Compound concentration required to reduce the viability of mock-infected HeLa cells by 50%, was reported.
|
[PMID: 7877145] |
| HeLa | EC50 |
1.76 μM
Compound: WIN-51711
|
In vitro concentration required to achieve 50% protection of HeLa cells from HRV-14 induced cytopathic effect
In vitro concentration required to achieve 50% protection of HeLa cells from HRV-14 induced cytopathic effect
|
[PMID: 7877145] |
| HeLa | EC50 |
2.35 μM
Compound: WIN-51711
|
In vitro concentration required to achieve 50% protection of HeLa cells from HRV-2 induced cytopathic effect
In vitro concentration required to achieve 50% protection of HeLa cells from HRV-2 induced cytopathic effect
|
[PMID: 7877145] |
| HeLa | IC50 |
1.5 μM
Compound: Disoxaril
|
Cytotoxicity against human HeLa Ohio-1 cells
Cytotoxicity against human HeLa Ohio-1 cells
|
[PMID: 18590964] |
| RD | CC50 |
167.39 μM
Compound: 5; WIN 51711
|
Cytotoxicity against human RD cells assessed as reduction in cell viability after 24 to 36 hrs by MTS-based CPE reduction assay
Cytotoxicity against human RD cells assessed as reduction in cell viability after 24 to 36 hrs by MTS-based CPE reduction assay
|
[PMID: 26885567] |
| RD | EC50 |
15.32 μM
Compound: 5; WIN 51711
|
Antiviral activity against Enterovirus 71 infected in human RD cells after 24 to 36 hrs by MTS-based CPE reduction assay
Antiviral activity against Enterovirus 71 infected in human RD cells after 24 to 36 hrs by MTS-based CPE reduction assay
|
[PMID: 26885567] |
| Vero | CC50 |
147.77 μM
Compound: 5; WIN 51711
|
Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 24 to 36 hrs by MTS-based CPE reduction assay
Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 24 to 36 hrs by MTS-based CPE reduction assay
|
[PMID: 26885567] |
| Vero | EC50 |
19.48 μM
Compound: 5; WIN 51711
|
Antiviral activity against Human enterovirus 71 infected in monkey African green Vero cells by MTS-based CPE reduction assay
Antiviral activity against Human enterovirus 71 infected in monkey African green Vero cells by MTS-based CPE reduction assay
|
[PMID: 26885567] |
Disoxaril (35-140 μM; 48 h) inhibits FL cell growth with a CGIC50 of 70 μM[1].
Disoxaril (0.03-0.3 μg/mL; 15 min preincubation) inhibits replication of poliovirus type 1 and type 2 in HeLa cells by stabilizing the virus capsid to block pH-dependent viral uncoating in endosomes and/or lysosomes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:FL cells
-
Concentration:2xCGIC50, 1xCGIC50, CGIC50/2, CGIC50/4, CGIC50/8 (CGIC50 = 70 μmol/l)
-
Incubation Time:48 h
-
Result:Reduced viable cell number to 27.70% of control at 2xCGIC50, 45.55% at 1xCGIC50, 50.06% at CGIC50/2, 59.04% at CGIC50/4, and 68.50% at CGIC50/8.
Achieved a CGIC50 of 70 μmol/l for FL cell growth inhibition.
Yielded a selectivity index (SI = IC50/CGIC50) of 233.3, with an IC50 of 0.3 μmol/l for poliovirus type 1 replication inhibition.
Showed additive or sub-additive cytotoxic effects when combined with enviroxime, with no synergistic cytotoxicity detected.
Chemical Information
-
CAS No. 87495-31-6
-
Appearance Solid
-
Masse moléculaire 342.43
-
Formule C20H26N2O3
-
Color White to off-white
-
SMILES
CC1=NOC(CCCCCCCOC2=CC=C(C3=NCCO3)C=C2)=C1
-
Synonyms
WIN-51711
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 3.33 mg/mL (9.72 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (269 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9203 mL | 14.6015 mL | 29.2030 mL | 73.0076 mL |
| 5 mM | 0.5841 mL | 2.9203 mL | 5.8406 mL | 14.6015 mL |
Disoxaril Related Classifications
HY-111233 Related Classifications
Powered by Bioz